Parthenolide Derivatives as PKM2 Activators Showing Potential in Colorectal Cancer

As a vital kinase in the glycolysis system, PKM2 is extensively expressed in colorectal cancer (CRC) to support the energy and biosynthetic needs. In this study, we designed a series of parthenolide (PTL) derivatives through a stepwise structure optimization, and an excellent derivate 29e showed good activity on PKM2 (AC(50) = 86.29 nM) and displayed significant antiproliferative activity against HT29 (IC50 = 0.66 mu M) and SW480 (IC50 = 0.22 mu M) cells. 29e decreased the expression of total PKM2, prevented nucleus translocation of PKM2 dimer, and inhibited PKM2/STAT3 signaling pathway. 29e remarkably increased OCR and decreased the extracellular acidification rate (ECAR). The antiproliferative effect of 29e depended on PKM2, and the Cys424 of PKM2 was the key binding site. Furthermore, 29e significantly suppressed tumor growth in the HT29 xenograft model without obvious toxicity. These outcomes demonstrate that 29e is a promising drug candidate for the treatment of CRC.

Automated summary

In this study, a potential drug candidate 29e for treating CRC was designed to inhibit tumor growth by targeting PKM2 kinase, demonstrating significant antiproliferative effects in cell experiments and animal models.